Publications by authors named "K Shide"
BACKGROUND Fibrosing mediastinitis (FM) is a rare, fibroproliferative disorder within the mediastinum. It is extremely rare for hematologic malignancies to develop as FM. CASE REPORT A 32-year-old Japanese man with a 1-month history of headache and 2-week history of facial swelling underwent chest computed tomography (CT); a diffuse mass-like lesion was revealed in the anterior mediastinum with severe stenosis of vital mediastinal organs.
View Article and Find Full Text PDFArticle Synopsis
- * Sixteen participants were treated with imeglimin over three months, but results showed no significant changes in their metabolic rates or body composition.
- * However, levels of growth differentiation factor 15 (GDF15) increased, suggesting it may serve as a potential marker for imeglimin's effectiveness in treating type 2 diabetes.
Article Synopsis
- A systematic review and meta-analysis was conducted to assess the impact of low-carbohydrate diets on glycemic control in East Asian adults with type 2 diabetes, as previous studies mainly focused on Western populations.
- The analysis included six randomized controlled trials that evaluated outcomes such as glycated hemoglobin levels, body mass index, and other health metrics over periods of 3 to 18 months.
- Results indicated that low-carbohydrate diets significantly reduced glycated hemoglobin levels and body mass index compared to control diets, suggesting that these dietary changes could be effective in managing glycemic control for at least 6 months in East Asians.
C-Mannosyl tryptophan (CMW), a unique glycosylated amino acid, is considered to be produced by degradation of C-mannosylated proteins in living organism. Although protein C-mannosylation is involved in the folding and secretion of substrate proteins, the pathophysiological function in the hematological system is still unclear. This study aimed to assess CMW in the human hematological disorders.
View Article and Find Full Text PDFAims/introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety. We therefore carried out a large-scale, non-commercial, investigator-initiated study on the safety and effectiveness of the SGLT2 inhibitor tofogliflozin.
View Article and Find Full Text PDF